A Study of Talquetamab for People With Multiple Myeloma Who Had CAR T Cell Therapy


Full Title

Talquetamab Consolidation after BCMA CART Cell Therapy for Relapsed or Refractory Multiple Myeloma


Researchers want to see if the drug talquetamab is useful for treating multiple myeloma. The people in this study have multiple myeloma that keeps growing even after treatment. They also recently received a CAR T cell therapy called idecabtagene autoleucel.

Talquetamab is designed to help the immune system destroy cancer cells. It is given as an injection under the skin.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have multiple myeloma that keeps growing even with treatment.
  • Had treatment with idecabtagene autoleucel within 1-3 months of entering the study.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Sham Mailankody’s office at 646-608-3712.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID